RX Biosyent Inc

BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today released a summary of its
financial results for the first quarter 2008. For the three months ending March
31, 2008, sales decreased by 4.9% from $302,840 in quarter one 2007 to $287,997
in quarter one 2008. The company incurred a loss of ($74,067) in quarter one
2008 compared to a loss of ($29,416) in quarter one 2007. This loss is
predominantly due to higher operating expenses leading up to the launch of
Ciprofloxacin Injection which was first shipped in May 2008 and lower sales of
Protect-It(R) in quarter one 2008 as compared to quarter one 2007.


Total working capital has decreased by approximately 9% from $1,097,489 on
December 31, 2007 to $1,002,858 on March 31, 2008. Cash and cash equivalents
account for 83% of working capital as of March 31, 2008.


Full details of 2008 quarter one results and Financial Statements and
Management's Discussion & Analysis will be posted on sedar.com on May 30, 2008.


At the request of the Ontario Securities Commission, BioSyent is also re-filing
the Certificates of the President and Chief Executive Officer and of the Chief
Financial Officer of the Company in respect of its annual filings for the year
ended December 31, 2007, which certificates were previously filed. The refiling
of these Certificates is necessary due to the use of outdated forms in the
previously filed Certificates. The Company is also refiling its annual MD&A to
reflect such revised annual certification and reference to the new certification
is contained in Section 11 of the annual MD&A, which is the only section of the
MD&A that has been changed.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024